Stock Analysis on Net
Stock Analysis on Net

Baxter International Inc. (NYSE:BAX)

This company has been moved to the archive! The financial data has not been updated since August 4, 2016.

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Baxter International Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
BioScience — 6,699 6,564 6,237 6,053
Medical Products 9,968 9,972 8,695 7,953 7,840
Net sales 9,968 16,671 15,259 14,190 13,893

Based on: 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31).

BioScience Segment Revenue
The revenue for the BioScience segment shows a steady upward trend from 2011 to 2014. The values increased each year from 6,053 million USD in 2011 to 6,699 million USD in 2014. However, there is no data available for 2015, which precludes analysis of the most recent year for this segment.
Medical Products Segment Revenue
The Medical Products segment exhibits consistent growth from 2011 through 2014. Revenue rose from 7,840 million USD in 2011 to 9,972 million USD in 2014, marking a substantial increase over the four-year period. In 2015, revenue remained nearly flat compared to 2014, showing a negligible decrease to 9,968 million USD.
Total Net Sales
Total net sales increased consistently from 13,893 million USD in 2011 to 16,671 million USD in 2014, indicating overall company growth during this period. However, in 2015, net sales decreased significantly to 9,968 million USD, a sharp decline from the previous year. This drop corresponds exactly with the Medical Products segment revenue figure for that year, suggesting that data for BioScience in 2015 is missing or excluded, which impacts the comprehensiveness of the total sales figure for 2015.
Overall Insights
From 2011 through 2014, both segments and total net sales demonstrated positive growth trends, with Medical Products showing a particularly pronounced increase. The stability in 2015 for Medical Products contrasts with the missing data for BioScience and the consequent sharp decline in total net sales, which implies incomplete reporting or potential structural changes affecting reported figures. The absence of 2015 data for BioScience limits the ability to conclusively determine whether the decline in total net sales reflects actual business performance or data omission.